Trial Profile
Drug Use-Results Survey of OPDIVO [unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 18 Oct 2022 Status changed from active, no longer recruiting to completed.
- 21 Sep 2020 Results assessing nivolumab safety data of 650 patients, presented at the 45th European Society for Medical Oncology Congress.
- 01 Oct 2018 Status has been changed to active, no longer recruiting.